Novo Nordisk Sues Eli Lilly, Alleging Misleading Obesity-Drug Ads

Novo Nordisk has sued rival Eli Lilly, accusing it of deceptive advertising in the fiercely competitive market for weight-loss drugs.

The complaint, filed July 21 in New Jersey federal court, alleges that Lilly’s marketing compared the highest doses of its obesity and diabetes drugs against lower, original doses of Novo’s products, creating a misleading impression of relative performance.

Why dose comparison is contestable

The specific allegation turns on something genuinely ambiguous rather than on a plain falsehood.

Both drugs are approved at multiple doses, and both were studied at those doses in separate trials conducted at different times. The highest approved dose of one against the originally studied dose of the other is a real comparison of real data — and not a like-for-like one.

What a fair comparison would be is not obvious. Highest approved dose against highest approved dose is defensible, but doses are not equivalent across different molecules, and the maximum tolerated dose differs. Comparing what most patients actually receive is arguably more relevant to practice and harder to define.

That ambiguity is why the dispute is a legal one about impression rather than a factual one about numbers.

The drugs and the ask

The dispute centres on Novo’s Wegovy (obesity) and Ozempic (diabetes), and Lilly’s Zepbound (obesity) and Mounjaro (diabetes).

Novo seeks a permanent injunction to pull the advertisements and wants Lilly to run a corrective advertising campaign.

“Ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns,” said Novo Nordisk general counsel John Kuckelman.

Corrective advertising is the more aggressive remedy and is rarely granted. It requires a court to find not only that advertising was misleading but that the impression persists and must be actively undone — a higher bar than simply stopping the campaign.

Lilly’s answer

Lilly defended its marketing, pointing to head-to-head data. “The gold standard for comparing medicines is a robustly designed, well-conducted head-to-head clinical trial — like Surmount-5,” the company said.

That is a strong position if the advertising rests on it. A head-to-head trial randomises patients to one drug or the other simultaneously, under identical conditions, which removes exactly the objections that apply to comparing separate trials.

Whether the specific advertisements Novo challenges relied on that trial or on cross-trial comparison is the substance of the case.

Why direct-to-consumer advertising is the arena

The United States is one of very few countries permitting prescription drug advertising to the public, which is why a dispute of this kind takes this form here and nowhere else.

Regulators require such advertising to present benefits and risks fairly, and enforcement is largely reactive. A competitor with commercial motive and legal resources frequently acts faster than a regulator, which is why company-versus-company litigation has become a significant mechanism of advertising oversight.

Why it matters

Lilly’s Zepbound generated about $4 billion in first-quarter 2026 revenue, ahead of Novo’s Wegovy at roughly $2.7 billion.

Novo had previously sent a cease-and-desist demand, which Lilly declined.

What the head-to-head trial actually found

The trial Lilly cites is the substance behind its defence, and its design is what gives the comparison weight.

Head-to-head trials directly comparing two active drugs are uncommon in pharmaceuticals, because companies have little incentive to run a study that could show their product is inferior. Most comparative claims therefore rest on comparing separate placebo-controlled trials, which differ in population, duration and conduct.

Surmount-5 randomised participants to tirzepatide or semaglutide simultaneously, under the same protocol, with the same assessments — which removes essentially every objection that applies to cross-trial comparison, and reported greater weight loss with tirzepatide.

The distinction that matters for the lawsuit is between citing that result and citing dose comparisons drawn from elsewhere. An advertisement resting on Surmount-5 stands on unusually solid ground; one presenting cross-trial dose comparisons does not become defensible merely because a head-to-head trial also exists.

Which is why the case will turn on what the specific advertisements said rather than on what evidence Lilly possesses.

The pattern this fits

Litigation between these two companies has become a recurring feature of the obesity market rather than an isolated dispute.

Both have pursued compounding pharmacies selling copies of their drugs during and after shortage periods. Both have contested patents in multiple jurisdictions. Both have competed for the same acquisition targets, with Novo losing Metsera to Pfizer in a public contest.

The intensity reflects how much is concentrated in a two-company market growing faster than almost any in pharmaceutical history. Share established now is expected to persist, because prescribers and payers settle into patterns and switching a patient who is doing well is uncommon.

Advertising matters more here than in most therapeutic areas for a specific reason: patients frequently arrive at appointments having decided which drug they want. Direct-to-consumer campaigns in this category are not building general awareness of a condition — they are influencing a brand choice the patient will bring to the clinician, which is why a comparative claim is worth going to court over.

With billions at stake and both companies racing for share, the courtroom has become another front in the obesity-drug war. The allegations are unproven and the case is ongoing. Business news, not medical or investment advice.